Article
Dialysis firm FMC sees 'balanced' impact from GLP-1 drugs on its patients
Rating:
0.0
Views:
66
Likes:
1
Library:
1
The world's leading dialysis provider Fresenius Medical Care (FMC) sees a "balanced" impact of the GLP-1 diabetes and weight-loss drugs on its patients, Chief Executive Helen Giza said during a post-earnings report call on Thursday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value